Radiopharm Theranostics (RAD) investor relations material

Company overview and strategy

• Focuses on radiopharmaceutical imaging and therapies, with a differentiated approach targeting mechanisms like PD-L1, HER2, and B7-H3, where there is little or no clinical development.

• Dual-listed on ASX and NASDAQ, with a management team primarily based in the US.

• Built a secure, redundant supply chain and established strategic partnerships with Lantheus and MD Anderson Cancer Center.

• Lantheus is a key industrial partner and largest shareholder, validating the company's direction.

• Recent capital raise extends cash runway into Q1 2027, supporting ongoing clinical development.

Pipeline and clinical progress

• Five molecules in clinical development: one imaging agent (RAD101) and four therapeutics (RAD204, RAD202, B7-H3, KLK3).

• RAD101, an imaging agent for brain metastasis, is in phase IIB with 12 of 30 patients enrolled; trial completion expected by Q1 2026.

• RAD204 (PD-L1 targeting) and RAD202 (HER2 targeting) are in dose escalation trials, with promising early safety and tumor uptake data.

• B7-H3 and KLK3 therapeutics expected to enter clinical stage by end of 2025, with IND approval for B7-H3 and first patient dosing planned for late 2024.

• All five molecules expected to be in the clinic by December.

Clinical data and market potential

• RAD101 addresses a large unmet need in brain metastasis imaging, offering improved differentiation between tumor and necrosis post-radiation compared to MRI alone.

• Early clinical data show promising results in patient management and potential for faster treatment decisions.

• Commercial assessment estimates US market potential for RAD101 at $500–$700 million annually, with minimal competition expected.

• RAD204 and RAD202 show favorable safety profiles and increased tumor uptake at higher doses, with early signs of disease stabilization.

• Key clinical readouts for RAD101, RAD204, and RAD202 are expected throughout 2026.